toremifene

Absorption: Well absorbed following oral administration.

Distribution: Widely distributed; 99% bound to plasma proteins.

Protein Binding: 99.5%.

Metabolism/Excretion: Extensively metabolized; undergoes enterohepatic circulation.

Half-Life: 5 days.

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	3 hr	4–6 wk‡

‡Steady-state blood levels occur after 4–6 wk.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
History of thromboembolic disease;
Congenital or acquired QT prolongation, hypokalemia, or hypomagnesemia;
Concurrent use of QT-interval prolonging medications or strong CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, and voriconazole);
OB: Pregnancy (may cause fetal harm);
Lactation: Lactation.

Use Cautiously in:

Bone metastases (↑ risk of hypercalcemia);
Heart failure;
Hepatic impairment;
Pre-existing endometrial hyperplasia (avoid long-term treatment).

Adv. Reactions/Side Effects ⬆ ⬇

CV: HF, MI, TORSADE DE POINTES, angina, arrhythmias, edema, QT interval prolongation, thrombophlebitis

Derm: sweating

EENT: blurred vision, cataracts, corneal keratopathy, dry eyes, glaucoma

F and E: hypercalcemia

GI: HEPATOTOXICITY, nausea, vomiting

GU: ENDOMETRIAL CANCER, vaginal discharge, endometrial hyperplasia/hypertrophy, uterine polyps, vaginal bleeding

Hemat: anemia

Neuro: depression, dizziness, headache, lethargy

Resp: PULMONARY EMBOLISM

Misc: hot flashes, tumor flare

Interactions ⬆ ⬇

Drug-drug:

QT-prolonging drugs may ↑ the risk of torsade de pointes; avoid concurrent use.
Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, and voriconazole may ↑ levels; avoid concurrent use.
Strong CYP3A4 inducers, including dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, and phenobarbital may ↓ levels.
Concurrent use of agents that urinary excretion of calcium (thiazide diuretics) may ↑ the risk of hypercalcemia.
May ↑ the effects of warfarin and phenytoin.

Drug-Natural Products:

St. John's wort may ↓ levels.

Route/Dosage ⬆ ⬇

PO (Adults ): 60 mg once daily.

Availability ⬆ ⬇

(Generic available)

Tablets: 60 mg

Assessment ⬆ ⬇

Assess for an increase in bone or tumor pain. May be indicative of tumor flare and hypercalcemia if during early therapy. Confer with health care professional regarding analgesics. This transient pain usually resolves despite continued therapy.
Gynecologic examinations should be done regularly; may cause variations in Papanicolaou and vaginal smears.

Lab Test Considerations:

Monitor CBC, platelets, and calcium levels prior to and periodically throughout therapy. May cause transient hypercalcemia in patients with metastases to bone. An estrogen receptor assay should be assessed prior to initiation of therapy.
- Monitor hepatic function tests periodically during therapy. May cause elevated serum AST, alkaline phosphatase, and bilirubin concentrations.

Implementation ⬆ ⬇

Hypokalemia and hypomagnesemia should be corrected prior to starting therapy.
PO: Administer once daily.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take medication exactly as directed. If a dose is missed, it should be omitted.
Advise patient to report bone pain to health care professional promptly. Pain may be severe. Inform patient that this may be an indication of the drug’s effectiveness and will resolve over time. Analgesics should be ordered to control pain.
Advise patient that medication may cause hot flashes. Notify health care professional if these become bothersome.
Instruct patient to notify health care professional promptly if pain or swelling of legs, shortness of breath, weakness, sleepiness, confusion, nausea, vomiting, dizziness, headache, loss of appetite, or blurred vision occurs. Patient should also report menstrual irregularities, vaginal bleeding, pelvic pain or pressure.
May cause vaginal bleeding. Advise patient of importance of baseline and annual gynecological exams during therapy and to notify health care professional if vaginal bleeding, changes in vaginal discharge, pelvic pain or pressure occur.
Rep: Medication may induce ovulation and may have teratogenic properties. Advise patient to use a nonhormonal method of contraception during and for 1 mo after the course of therapy and to avoid breastfeeding during therapy.

Evaluation/Desired Outcomes ⬆ ⬇

Decrease in the size or spread of breast cancer.

US Brand Names ⬆ ⬇

Pot. Nursing Diagnoses ⬆ ⬇

Acute pain(Adverse Reactions)

Code ⬆

NDC Code

42747- KYOWA KIRIN, INC,
- 42747-327- Fareston
  - 42747-327-30- 30 TABLET in 1 BOTTLE (42747-327-30)

42747- KYOWA KIRIN, INC,
- 42747-327- Fareston
  - 42747-327-72- 7 TABLET in 1 BLISTER PACK (42747-327-72)

64980- Rising Pharmaceuticals, Inc.
- 64980-404- Toremifene Citrate
  - 64980-404-03- 30 TABLET in 1 BOTTLE, PLASTIC (64980-404-03)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇